UCLA loses federal research funding in administration's ongoing fight with top universities
'This is not only a loss to the researchers who rely on critical grants,' wrote Chancellor Julio Frenk. 'It is a loss for Americans across the nation whose work, health, and future depend on the groundbreaking work we do.'
Grants from the National Science Foundation and the National Institutes of Health are included in the suspensions, Frenk said, but did not provide an amount of how much funding is in peril. The Los Angeles Times reported that roughly $200 million in grants awarded to UCLA are being suspended, citing a partial list of suspended grants provided to them by a source.
A spokesperson for the National Science Foundation declined to provide specific figures, saying grant awards are being suspended 'because they are not in alignment with current NSF priorities and/or programmatic goals.'
'We will not fund institutions that promote antisemitism,' said a spokesperson for the Department of Health and Human Services, which includes the National Institutes of Health. 'We will use every tool we have to ensure institutions follow the law.'
The Trump administration has repeatedly cited antisemitism – especially in the context of contentious pro-Gaza protests on campuses – as a reason to deny promised funds to universities, including Harvard and Columbia. Harvard is fighting the funding decisions in court, while Columbia agreed to a settlement with the government that restored its grants.
The funding cut comes days after the Justice Department's Civil Rights Division announced it found UCLA in violation of federal law by 'acting with deliberate indifference in creating a hostile educational environment for Jewish and Israeli students.'
While the formal notice to UCLA said the federal government 'now seeks to enter into a voluntary resolution agreement,' Attorney General Pam Bondi sounded less conciliatory.
'DOJ will force UCLA to pay a heavy price for putting Jewish Americans at risk and continue our ongoing investigations into other campuses in the UC system,' Bondi said in a statement.
It is not just the Trump administration that has tangled with UCLA over charges of antisemitism. A group of Jewish students filed suit against the university last June, saying the school allowed discrimination against Jews to flourish following Israel's military operation in Gaza in response to the October 7 attacks.
The lawsuit said UCLA leaders waited days before responding to a group of pro-Palestinian protesters that refused to allow students to enter campus unless they agreed to 'a statement pledging their allegiance to the activists' views.'
UCLA settled the lawsuit earlier this week for $6.45 million, with more than $2 million of the total going to designated 'organizations that combat antisemitism and support the UCLA Jewish community.'
UCLA also agreed it is prohibited from 'knowingly allowing or facilitating the exclusion of Jewish students, faculty, and/or staff' from university programs and activities.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
A Tunisian musician was detained in LA after living in US for a decade. His doctor wife speaks out
LOS ANGELES (AP) — Dr. Wafaa Alrashid noticed fewer of her patients were showing up for their appointments at the Los Angeles area hospital where she works as immigration raids spread fear among the Latino population she serves. The Utah-born chief medical officer at Huntington Hospital understood their fear on a personal level. Her husband Rami Othmane, a Tunisian singer and classical musician, began carrying a receipt of his pending green card application around with him. Over the past few months, immigration agents have arrested hundreds of people in Southern California, prompting protests against the federal raids and the subsequent deployment of the National Guard and Marines. Despite living in the U.S. for a decade as one of thousands of residents married to U.S. citizens, he was swept up in the crackdown. On July 13, Othmane was stopped while driving to a grocery store in Pasadena. He quickly pulled out his paperwork to show federal immigration agents. 'They didn't care, they said, 'Please step out of the car,'' Alrashid recalled hearing the officers say as she watched her husband's arrest in horror over FaceTime. Alrashid immediately jumped in her car and followed her phone to his location. She arrived just in time to see the outline of his head in the back of a vehicle driving away. 'That was probably the worst day of my life," she said. The Trump administration's crackdown on illegal immigration has ensnared not only immigrants without legal status but legal permanent residents like Othmane who has green cards. Some U.S. citizens have even been arrested. Meanwhile, many asylum-seekers who have regular check-in appointments are being arrested in the hallways outside courtrooms as the White House works toward its promise of mass deportations. Alrashid said her husband has been in the U.S. since 2015 and overstayed his visa, but his deportation order was dismissed in 2020. They wed in March 2025 and immediately filed for a green card. After his arrest, he was taken to the U.S. Immigration and Customs Enforcement facility in downtown Los Angeles where he was held in a freezing cold room with 'no beds, no pillows, no blankets, no soap, no toothbrushes and toothpaste, and when you're in a room with people, the bathroom's open,' she said. The Department of Homeland Security in an emailed statement noted the expiration of his tourist visa but did not address the dismissal of the deportation order in 2020 nor his pending green card application. The agency denied any allegations of mistreatment, and said "ensuring the safety, security, and well-being of individuals in our custody is a top priority at ICE.' Alrashid said for years her husband has performed classical Arabic music across Southern California. They first met when he was singing at a restaurant. 'He's the kindest person,' Alrashid said, adding that he gave a sweater she brought him to a fellow detainee and to give others privacy, he built a makeshift barrier around the open toilet using trash bags. 'He's brought a lot to the community, a lot of people love his music," she said. More than a week after his arrest, fellow musicians, immigration advocates and activists joined Alrashid in a rally outside the facility. A few of his colleagues performed classical Arabic music, drumming loud enough that they hoped the detainees inside could hear them. Los Jornaleros del Norte musicians, who often play Spanish-language music at rallies, also were there. 'In Latin American culture, the serenade — to bring music to people — is an act of love and kindness. But in this moment, bringing music to people who are in captivity is also an act of resistance," said Pablo Alvarado, co-executive director of the National Day Laborer Organizing Network. Leading up to the rally, Alrashid was worried because she hadn't received her daily call from her husband and was told she couldn't visit him that day at the detention facility. She finally heard from him that evening. Othmane told her over the phone he was now at an immigration detention facility in Arizona, and that his left leg was swollen. 'They should ultrasound your leg, don't take a risk,' she said. Alrashid hopes to get her husband out on bail while his case is being processed. They had a procedural hearing on Thursday where the judge verified his immigration status, and have a bail bond hearing scheduled for Tuesday. Until then, she'll continue waiting for his next phone call.
Forbes
an hour ago
- Forbes
Novel Access Model For Sickle Cell Disease Gene Therapy Could Be Template
The Centers for Medicare and Medicaid Services announced in July that 33 states, the District of Columbia and Puerto Rico will join a new voluntary program intended to improve patient access to and lower costs for gene therapies targeting sickle cell disease. This was a Biden administration initiative, which the Trump administration decided to continue to implement. It ties payment for two novel gene therapies to positive clinical outcomes. This could make such treatments that cost millions be more widely accessible for patients. And if successful, it may serve as a template for future cell and gene therapy agreements. Medicaid, the joint federal and state program that provides health coverage to low-income individuals, is the main insurer for SCD patients. The Biden administration announced last year that the manufacturers of Lyfgenia and Casgevy had entered into agreements with CMS to participate in the Cell and Gene Therapy Access Model, which allows CMS to negotiate outcomes-based agreements on behalf of state Medicaid programs for cell and gene therapies, beginning with sickle cell disease treatments. Essentially this means that CMS will reimburse based on whether certain agreed-upon clinical thresholds are reached in patients. According to CMS, the participating states in the newly established access initiative represent about 84% of Medicaid beneficiaries with SCD. The program could contribute towards a sizable expansion of access to potentially transformative care in the form of two extraordinarily expensive gene therapies. The launch prices for Casgevy (exagamglogene autotemcel) and Lyfgenia (lovotibeglogene autotemcel) were $2.2 million and $3.1 million, respectively. SCD is a group of congenital red blood cell disorders, named sickle cell for their crescent shape. The condition affects millions of people worldwide. In the United States, approximately 100,000 individuals are living with the disease, which predominantly impacts people of sub-Saharan African descent. The disease alters the structure of hemoglobin, the molecule in red blood cells that delivers oxygen to organs and tissue throughout the body. As a consequence, this causes severe pain, anemia, organ damage and infections. Individuals with the disease have a shorter life expectancy, by more than 20 years on average. The most common sickle cell disorder type is sickle cell anemia. Besides pain medications to relieve symptoms as well as antibiotics to treat infections, hydroxyurea—a bone marrow suppressive agent that decreases red blood cell production—can be used to reduce the frequency of painful episodes. It has been in use since the 1980s. The Food and Drug Administration has approved several new therapeutics in the past ten years, but none are as promising as Lyfgenia and Casgevy. These two novel therapies can decrease or potentially eliminate pain crises in patients. Gene therapies such as Lyfgenia and Casgevy are administered in an inpatient hospital setting but are considered covered outpatient drugs because they're directly reimbursed and subject to standard, federally mandated Medicaid rebates. Manufacturers of the two treatments must also provide states with supplemental rebates (post-hoc discounts off of the list price) reflecting model-negotiated terms. In turn, states are obligated to implement an agreed-upon access policy for patients. According to CMS, there is also optional federal support of up to $9.55 million per state available to help with implementation of the arrangements, outreach and data tracking. In the cell and gene therapy space, science has generally outpaced commercialization. Access to very costly treatments is a challenge. Whether in the public or commercial sector, payers must find novel ways of paying for cell and gene therapies while generating evidence with respect to their real-world effectiveness and safety. Questions insurers must find answers to include: What are the health outcomes for patients in real-world settings? Do treatments fulfill the promise of a one-time cure for certain serious illnesses or disorders? Are there particular safety concerns that appear in real-world settings? Are side effects manageable? Coordinating evidence gathering as well as contracts across state Medicaid agencies is likely to yield a more efficient process while improving access for a substantial majority of SCD sufferers nationwide. It's not just SCD gene therapies that confront a formidable set of barriers to access. All cell and gene therapy manufacturers face a challenging environment. The regulatory hurdles are enormous to begin with, but manufacturing challenges following approval are considerable, too. Furthermore, patient preparation, side effect and adverse event profiles can be intolerable. This can deter patients from signing up to initiate treatment. On top of all of this, payers concerned about the high per unit costs often impose coverage restrictions, as the Tufts Center for the Evaluation of Value and Risk in Health describes. Nonetheless, gene therapies in particular hold the promise of delivering groundbreaking improvements in health outcomes across multiple disease areas. Therefore, overcoming obstacles to optimal patient access is crucial. If successful, the SCD model being experimented with could serve as a blueprint for other cell and gene therapies that have faced considerable barriers with respect to patient access.
New York Times
an hour ago
- New York Times
Her Dispensary Was Set to Open. Then New York Got in the Way.
After trying to open a legal cannabis dispensary in New York for three years, Nubia Ashley was close to achieving her goal, possibly as soon as this month. Then on Monday, she got an email from the state's cannabis agency admitting that it had made a significant error. The agency, which had approved her store's location in March, said the address was closer to a nearby school than the 500 feet allowed by state law. It was the agency's fault that the distance had been measured incorrectly, the email said, but Ms. Ashley would need to move. 'I'm trying to remain as positive as I possibly can because I was like this close to open, just so close,' Ms. Ashley, 37, said. 'And then I get hit with this letter.' The jarring message was a result of a sudden policy shift that threw the future of more than 150 existing and planned dispensaries into question. Regulators had previously measured the 500-foot distance from a dispensary's entrance to a school's. But on Monday, officials said the distance should have been measured from the school's property line. An intense backlash from some license-holders, lawmakers and former regulators followed. They questioned why Gov. Kathy Hochul's administration had made such an abrupt change that could hurt people who followed the state's rules. Several lawsuits are in the works that could ultimately cost New York taxpayers millions of dollars in damages. Want all of The Times? Subscribe.
